Elan/Biogen Idec Antegren Will Set Premium Price In Multiple Sclerosis
This article was originally published in The Pink Sheet Daily
Executive Summary
The pricing model anticipates future indications for Antegren, including Crohn’s and rheumatoid arthritis. Current MS therapies Avonex and Rebif are priced at roughly $1,000 and $1,400 per month, respectively.
You may also be interested in...
Elan/Biogen Idec's Tysabri, Formerly Antegren, Approved For MS Based On One-Year Data
Monoclonal antibody's label includes studies as monotherapy and as add-on in patients previously treated with Avonex. Two-year results are expected in the first half of 2005.
Elan/Biogen Idec's Tysabri, Formerly Antegren, Approved For MS Based On One-Year Data
Monoclonal antibody's label includes studies as monotherapy and as add-on in patients previously treated with Avonex. Two-year results are expected in the first half of 2005.
Antegren BLA Submission For Multiple Sclerosis Could See Approval By Year-End
Biogen Idec and Elan are requesting priority review for the MS submission. Companies are also seeking accelerated approval; BLA is based on one-year data from ongoing AFFIRM and SENTINEL trials.